Hamza Hashmi, MD

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

In this fifth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, reviews the implications of up-front vs delayed transplant on survival, quality of life, and risk of secondary malignancies in newly diagnosed, multiple myeloma.

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.